Silencing the Peroxiredoxin III gene inhibits cell proliferation in breast cancer

International Journal of Oncology

Volumn 36, Issue 2, 2010, Pages 359-364

  Chua, Pei Jou ^a   Lee, Eng Hong ^a   Yu, Yingnan ^a   Yip, George Wai Cheong ^a   Tan, Puay Hoon ^a,b   Bay, Boon Huat ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Breast cancer; Cell cycle; Cell proliferation; Peroxiredoxin III; siRNA

Indexed keywords

CYCLINE; ENZYME ANTIBODY; PEROXIREDOXIN; PEROXIREDOXIN 3; PEROXIREDOXIN 3 ANTIBODY; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; GENE FUNCTION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; WESTERN BLOTTING;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE SILENCING; HUMANS; IMMUNOHISTOCHEMISTRY; PEROXIREDOXINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TISSUE ARRAY ANALYSIS; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 75449110199     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000507     Document Type: Article

References (35)

1. Stewart BW and Kleihues P: World Cancer Report. IARC Press, Lyon, 2003.
2. Stingl J and Caldas C: Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer 7: 791-799, 2007.
3. Vargo-Gogola T and Rosen JM: Modelling breast cancer: one size does not fit all. Nat Rev Cancer 7: 659-672, 2007.
4. Kim HK, Kim SJ, Lee JW, Lee JW, Cha MK and Kim IH: Identification of promoter in the 5′-flanking region of the E. coli thioredoxin-linked thiol peroxidase gene: evidence for the existence of oxygen-related transcriptional regulatory protein. Biochem Biophys Res Commun 221: 641-646, 1996.
5. Chae HZ, Robison K, Poole LB, Church G, Storz G and Rhee SG: Cloning and sequencing of thiol-specific antioxidant from mammalian brain: alkyl hydroperoxide reductase and thiolspecific antioxidant define a large family of antioxidant enzymes. Proc Natl Acad Sci USA 91: 7017-7021, 1994.
6. Hofmann B, Hecht HJ and Flohe L: Peroxiredoxins. Biol Chem 383: 347-364, 2002.
7. Rhee SG, Kang SW, Chang TS, Jeong W and Kim K: Peroxiredoxin, a novel family of peroxidases. IUBMB Life 52: 35-41, 2001.
8. Wood ZA, Schroder E, Robin HJ and Poole LB: Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci 28: 32-40, 2003.
9. Verdoucq L, Vignols F, Jacquot JP, Chartier Y and Meyer Y: In vivo characterization of a thioredoxin h target protein defines a new peroxiredoxin family. J Biol Chem 274: 19714-19722, 1999.
10. Fujii J and Ikeda Y: Advances in our understanding of peroxiredoxin, a multifunctional, mammalian redox protein. Redox Rep 7: 123-130, 2002.
11. Rhee SG, Chae HZ and Kim K: Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic Biol Med 38: 1543-1552, 2005.
12. Araki M, Nanri H, Ejima K, Murasato Y, Fujiwara T, Nakashima Y and Ikeda M: Antioxidant function of the mitochondrial protein SP-22 in the cardiovascular system. J Biol Chem 274: 2271-2278, 1999.
13. Watabe S, Hiroi T, Yamamoto Y, Fujioka Y, Hasegawa H, Yago N and Takahashi SY: SP-22 is a thioredoxin-dependent peroxide reductase in mitochondria. Eur J Biochem 249: 52-60, 1999.
14. Wonsey DR, Zeller KI and Dang CV: The c-Myc target gene PRDX3 is required mitochondrial homeostasis and neoplastic transformation. Proc Natl Acad Sci USA 99: 6649-6654, 2002.
15. Choi JH, Kim TN, Kim S, Baek SH, Kim JH, Lee SR and Kim JR: Overexpression of mitochondrial thioredoxin reductase and peroxiredoxin III in hepatocellular carcinomas. Anticancer Res 22: 3331-3335, 2002.
16. Noh DY, Ahn SJ, Lee RA, Kim SW, Park IA and Chae HZ: Overexpression of peroxiredoxin in human breast cancer. Anticancer Res 21: 2085-2090, 2001.
17. Karihtala P, Mantyniemi A, Kang SW, Kinnula VL and Soini Y: Peroxiredoxins in breast carcinoma. Clin Cancer Res 9: 3418-3424, 2003.
18. Chang TS, Cho CS, Park S, Yu S, Kang SW and Rhee SG: Peroxiredoxin III, a mitochondrion-specific peroxidase, regulates apoptotic signaling by mitochondria. J Biol Chem 279: 41975-41984, 2004.
19. Nonn L, Berggren M and Powis G: Increased expression-of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide-dependent apoptosis. Mol Cancer Res 1: 682-689, 2003.
20. Aaltomaa S, Lipponen P and Syrjanen K: Proliferating cell nuclear antigen (PCNA) immunolabeling as a prognostic factor in axillary lymph node negative breast cancer. Anticancer Res 13: 533-538, 1993.
21. Tsurimoto T: PCNA, a multifunctional ring on DNA. Biochim Biophys Acta 1443: 23-39, 1998.
22. Cao J, Schulte J, Knight A, Leslie NR, Zagozdzon A, Bronson R, Manevich Y, Beeson C and Neumann CA: Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity. EMBO J 28: 1505-1517, 2009.
23. Wang T, Tamae D, LeBon T, Shively JE, Yen Y and Li JJ: The role of peroxiredoxin II in radiation-resistant MCF-7 breast cancer cells. Cancer Res 65: 10338-10346, 2005.
24. Chua PJ, Yip GW and Bay BH: Cell cycle arrest induced by hydrogen peroxide is associated with modulation of oxidative stress related genes in breast cancer cells. Exp Biol Med (Maywood) 234: 1086-1094, 2009.
25. Droge W: Free radicals in the physiological control of cell function. Physiol Rev 82: 47-95, 2002.
26. Visconti R and Grieco D: New insights on oxidative stress in cancer. Curr Opin Drug Discov Dev 12: 240-245, 2009.
27. Fang J, Seki T and Maeda H: Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Adv Drug Deliv Rev 61: 290-302, 2009.
28. 2 scavenging and signaling. Antioxid Redox Signal 10: 1565-1576, 2009.
29. Matsukawa J, Matsuzawa A, Takeda K and Ichijo H: The ASK1-MAP kinase cascades in mammalian stress response. J Biochem 136: 261-265, 2004.
30. Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D and Piccart MJ: Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol 16: 1723-1739, 2005.
31. Ahlin C, Zhou W, Holmqvist M, Holmberg L, Nilsson C, Jirström K, Blomqvist C, Amini RM and Fjällskog ML: Cyclin A is a proliferative marker with good prognostic value in node-negative breast cancer. Cancer Epidemiol Biomarkers Prev 18: 2501-2506, 2009.
32. Habashy HO, Powe DG, Staka CM, Rakha EA, Ball G, Green AR, Aleskandarany M, Paish EC, Douglas Macmillan R, Nicholson RI, Ellis IO and Gee JM: Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen. Breast Cancer Res Treat (In press).
33. Pedersen MØ, Larsen A, Stoltenberg M and Penkowa M: The role of metallothionein in oncogenesis and cancer prognosis. Prog Histochem Cytochem 44: 29-64, 2009.
34. Lim D, Jocelyn KM, Yip GW and Bay BH: Silencing the Metallothionein-2A gene inhibits cell cycle progression from G1- to S-phase involving ATM and cdc25A signaling in breast cancer cells. Cancer Lett 276: 109-117, 2009.
35. Nikolova V, Koo CY, Ibrahim SA, Wang Z, Spillmann D, Dreier R, Kelsch R, Fischgräbe J, Smollich M, Rossi LH, Sibrowski W, Wülfing P, Kiesel L, Yip GW and Götte M: Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression. Carcinogenesis 30: 397-407, 2009.